Home � Products & Services � Best Practice Database � Clinical Operations � Communicating Clinical Trial Results

Communicating Clinical Trials to Avoid the Class Effect and Build a Halo Effect on Other Indications

ID: 4432

Features:

Words: 1,756

Published: Pre-2020

Delivery Format: Online PDF Document

License Options:
$824.95 - 1 user
$2474.85 - Up to 5 users
$4124.75 - Up to 20 users

Buy Now

919-403-0251

Schedule a Meeting

STUDY OVERVIEW
BENCHMARK CLASS
SPECIAL OFFER

This 5-page document contains best practices and supporting graphics related to using clinical trial results to avoid the class effect and create a halo effect for other indications a product may have. Companies run the risk of having physicians interpret the results of a landmark clinical study for a specific product to apply to the drug class as a whole. This document includes practices to avoid that class effect. It also includes information about leveraging success shown for a given indication in a clinical trial to boost sales of the product for other indications. This research comes from Best Practices, LLC's consulting services.

Industries Profiled:
Pharmaceutical; Biotech; Health Care

Companies Profiled:
Abbott Laboratories; Sanofi-aventis; AstraZeneca; Bristol-Myers Squibb; Eli Lilly; GlaxoSmithKline; Janssen; Merck; Pharmacia; Novartis; Schering-Plough

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.